29.01.2015 - Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.
Although the European stock markets are registering a boom, some biotechs still feel safer in the tried-and-tested US waters. Danish clinical stage biopharma company Ascendis Pharma has successfully raised US$108m (€95.5) by offering 6 million shares at US$18 (€16m). The Copenhagen-based company can be pleased with the result – initially they had offered only 5 million shares, with a price range of US$16 to US$18. Ascendis will trade under the ticker symbol "ASND."
Meanwhile, Irish biotech Nexvet has announced the terms for its own IPO on the other side of the Atlantic. The Dublin-based clinical-stage biopharmaceutical company develops therapeutic monoclonal antibodies for pets. Nexvet also plans to list on NASDAQ and wants to raise US$58m (€51m), with each of the 4 million shares offered for US$13 to US$16 (€11.5 to €14.1).
Continuing the recent rush of European stock markets listings, Liverpool-based Redx Pharma announced this week it would be staying this side of the pond for its €105m initial public offering: the drug developer aims to float on the London Stock Exchange AIM.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.